J

Johnson & Johnson

Makes prescription drugs and medical devices

Principal Engineer Platform/Cloud Engineering

Full-TimeUpdated on 10/23/2026Deadline 11/3/26
$102k - $175.9k
Senior
Bachelor's, Master's
Spring House, PA, USA+5 moreMore locations: Leiden, Netherlands | Raritan, NJ, USA | Maidenhead, UK | Madrid, Spain | Beerse, Belgium
HybridHybrid-work options are listed. Role description also names Leiden, Madrid, and Maidenhead.
DevOps & InfrastructurePlatform Engineering, Cloud Engineering

About the job

Requirements
  • A minimum of a Bachelor's degree in Computer Science, Bioinformatics, Computational Science, or a related field and a minimum of 6 years of industry experience, or a Master's degree in Computer Science, Bioinformatics, Computational Science, or a related field and a minimum of 4 years of industry experience.
  • Ability to lead technology platforms, programs, and projects and apply technical acumen to create new opportunities.
  • Experience with Python, Java, C++, or a related complex programming language.
  • Experience with AWS EC2 and S3.
  • Experience with AWS RDS.
  • Experience with AWS Lambda.
  • Hands-on GraphQL API implementation experience.
  • Experience with visualization technologies and techniques.
  • Experience with container functionality, including Docker, Singularity, or Kubernetes, and AWS EKS.
  • Experience with GPUs for computational sciences, advanced AI, machine learning, deep learning image analysis, and predictive model training.
  • Experience working with high-performance storage solutions.
  • Experience with Windows platform functionality.
  • Experience with Linux platform functionality.
  • Experience with technical vendor management.
  • Experience working on cross-functional and global teams.
  • Experience working in a fast-paced collaborative environment.
Responsibilities
  • Contribute to setting technology strategy and roadmaps, and lead and implement technology deployments for business partners in AI Native Drug Discovery and related disciplines.
  • Maintain strong partnerships with business partners in Therapeutics Discovery, Therapeutic Areas, Data Sciences, and other groups according to incoming demand.
  • Provide technology expertise to identify and assess areas of greatest opportunity and impact for AI Native Drug Discovery technology platforms in pharmaceutical research and development, and execute platform capabilities.
  • Collaborate with groups across the IT organization, engage and influence sector and enterprise technology leadership, and partner externally with the Life Sciences industry community.
  • Drive the team's technology stack, including capabilities for scheduling, communication, monitoring, reporting, alerting, deployment, orchestration, configuration management, infrastructure, reuse, and reproducibility.
  • Use cloud computing capabilities to deliver effective solutions.
  • Establish sustainable long-term operational processing and resource models.
  • Track changes in technology and incorporate containerization, serverless, accelerated AI, machine learning, deep learning, and agentic AI as appropriate to deliver business value.
  • Design and develop generative and agentic AI platforms, including large language model-powered applications, autonomous and multi-agent workflows, retrieval-augmented generation, and model orchestration to accelerate drug discovery workflows.
  • Build and operationalize cloud solutions on AWS or Azure using comparable foundation models, establishing reusable patterns for prompt engineering, tool/function calling, agent orchestration, evaluation, and responsible AI guardrails.
  • Provide technology leadership to learn from, develop, support, and motivate junior team members.
Desired Qualifications
  • Experience building generative or agentic AI solutions with AWS Bedrock, Anthropic Claude, or similar foundation models.
  • Experience with agent frameworks and retrieval-augmented generation architectures, such as LangChain, LangGraph, LlamaIndex, Strands, and vector databases.
  • Familiarity with management and analysis technologies in drug discovery.
  • Experience working with Chef for configuration management.
  • Hands-on experience building generative or agentic AI solutions with AWS Bedrock, Claude, or similar foundation models.
  • Experience implementing GxP projects.
  • Experience working with Agile methodology.
  • Experience working with high-performance computing cluster technologies, such as Grid Engine or Slurm.
  • Experience with other major cloud providers such as Microsoft Azure and Google Compute Engine.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.